BXLT - Baxalta Incorporated

Discussion in 'Stock Message Boards NYSE, NASDAQ, AMEX' started by T0rm3nted, Apr 6, 2016.

  1. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    8,447
    Likes Received:
    3,268
    Baxalta (BXLT) (Bax, taken from its former parent company and Alta taken from the Latin Altus which translates as 'high' or 'profound') is a biopharmaceutical company founded on 1 July 2015 after its parent company, Baxter International, spun off biopharmaceutical division with revenue of $6 billion.

    Baxalta inherited all of its parent company's on-the-market treatments, focused on hemophilia, The company aims to launch 20 in-development projects by 2020, heaping $2.5 billion in annual sales. Before being spun off, Baxalta acquired SuppreMol for $225 million. Baxalta also acquired the blockbuster leukemia drug Oncaspar from Sigma-Tau Finanziaria S.p.A. for $900 million.

    In August 2015, Shire Plc made an unsolicited $30.6 billion stock offer for the company sending the Baxalta share price up over 16%. Baxalta investors would be set to receive 0.1687 of Shire's American Depositary Receipts for every share they hold, representing a premium of 36% when compared to the company's stock price as of August 3. This deal would also be set to create the largest global biotech company focused solely on rare diseases. In January 2016, after 6 months of negotiations, the company agreed to be acquired by Shire for $32 billion.
     
  2. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    8,447
    Likes Received:
    3,268
    Baxalta Adynovate Gets Japanese Approval for Hemophilia A

    Baxalta Incorporated (BXLT) announced that its hemophilia drug, Adynovate, has received a regulatory nod from the Japanese Ministry of Health, Labour and Welfare for the treatment of patients 12 years and older with hemophilia A. The drug was approved as a twice-weekly dosing schedule.

    Adynovate is an extended circulating half-life recombinant factor VIII (rFVIII), based on Advate (Baxalta’s hemophilia A drug), a full-length FVIII molecule.

    With this approval, Adynovate’s marketing authorization gets transferred from Baxter Limited to Baxalta Japan Limited.

    According to a survey conducted by the World Federation of Hemophilia, the Japanese approval of Adynovate will extend its access to about 5,000 people in the country.

    We remind investors that Adynovate is currently approved in the U.S. for the on-demand treatment and control of bleeding episodes, and routine prophylaxis to reduce the frequency of bleeding episodes in adolescent and adults (12 years and older) suffering from hemophilia A.

    Moreover, a supplemental Biologics License Applications for Adynovate has been submitted to the FDA for the treatment of children under the age of 12 with hemophilia A, and for use in surgical settings. Adynovate (EU: Adynovi) is also under review in the EU for the treatment of pediatric, adolescent and adult patients with hemophilia A, and for use during surgery.

    We note that Baxalta had developed Adynovate in collaboration with Nektar Therapeutics (NKTR), using the latter’s PEGylation technology.

    Currently approved drugs in the hematology space include Eloctate, Kovaltry, Obizur and Nuwiq among others.

    Baxalta currently has a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector are AMAG Pharmaceuticals, Inc. (AMAG) and Emergent BioSolutions, Inc. (EBS), both sporting a Zacks Rank #1 (Strong Buy).
     

Share This Page